82.9 F
New York
Friday, June 21, 2024

CDC Issues Warning to Stop Using Eye Drops After 1 Death, Dozens of Infections Reported

Related Articles


Must read

Getting your Trinity Audio player ready...

EzriCare disputes agency’s claims, says it has received no consumer complaints

By: Jack Phillips

A brand of over-the-counter eye drops could be linked to a bacterial infection that left one person dead, the Centers for Disease Control and Prevention (CDC) said in a notice urging consumers to stop using EzriCare Artificial Tears while an investigation is underway.

The CDC said (pdf) in a document circulated by the American Academy of Ophthalmology (AAO) that it has identified at least 50 people in 11 states with Pseudomonas aeruginosa, a type of antibiotic-resistant bacteria. Cases in California, Colorado, Connecticut, Florida, New Jersey, New Mexico, New York, Nevada, Texas, Utah, and Washington have been reported so far, according to the agency.

“These specimens were collected in both outpatient and inpatient healthcare settings,” the letter reads. “Patient outcomes include permanent vision loss resulting from ocular infection, hospitalization, and death of one patient with bloodstream infection.”

A majority of people used EzriCare Artificial Tears before they developed an infection, the CDC stated.

“At this time, CDC recommends clinicians and patients stop using EzriCare Artificial Tears products pending additional guidance from CDC and FDA [Food and Drug Administration],” the CDC said in a Feb. 1 statement.

Maroya Spalding Walters, head of the CDC’s antimicrobial team, told NBC News that the eye drops haven’t definitively been linked to the bacteria. The CDC is working with the FDA along with state and local officials to investigate.

“To my knowledge, this is the first time that these highly resistant organisms have been linked to a contaminated product,” Walters said.


But in a statement countering the CDC’s claims, EzriCare stated that it hasn’t seen testing linking its eye drops to the antibiotic-resistant bacteria. However, the firm stated that it will discontinue distributing the eye drops.

“As of today, we are not aware of any testing that definitively links the Pseudomonas aeruginosa outbreak to EzriCare Artificial Tears. Nonetheless, we immediately took action to stop any further distribution or sale of EzriCare Artificial Tears. To the greatest extent possible, we have been contacting customers to advise them against continued use of the product,” EzriCare stated.

The firm stated that it first received a CDC notice of an investigation on Jan. 20 and hasn’t received any consumer complaints of an adverse report linked to its products.

“To the greatest extent possible, we have been contacting customers to advise them against continued use of the product. We also immediately reached out to both CDC and FDA and indicated our willingness to cooperate with any requests they may have of us,” stated EzriCare, which noted that the eye drops were manufactured in India by Global Pharma Healthcare PVT Limited and imported into the United States by Aru Pharma Inc.

EzriCare further noted that its “only role in introducing the product to the market was to design an exterior label and to market it to our customers” and that it has “no role in the formulation” or manufacturing of the product, according to the statement.

The CDC letter states that 50 people have been infected across the United States, with 38 cases being part of four “facility clusters” collected between May 2022 and December of 2022.

“In addition to demonstrating carbapenem resistance, isolates in this cluster are resistant to ceftazidime and cefepime,” two antibiotic drugs, the CDC stated. “The subset of isolates that underwent antimicrobial susceptibility testing for ceftazidime-avibactam and ceftolozane-tazobactam were also resistant to these agents.”


balance of natureDonate

Latest article

- Advertisement -